Monoclonal gammopathy of undetermined significance: A consensus statement: Guideline

James R. Berenson, Kenneth C. Anderson, Robert A. Audell, Ralph V. Boccia, Morton Coleman, Meletios A. Dimopoulos, Matthew M Drake, Rafael Fonseca, Jean Luc Harousseau, Douglas Joshua, Sagar Lonial, Ruben Niesvizky, Antonio Palumbo, G. David Roodman, Jesus F. San-Miguel, Seema Singhal, Donna M. Weber, Maurizio Zangari, Eric Wirtschafter, Ori YellinRobert A. Kyle

Research output: Contribution to journalArticle

78 Citations (Scopus)

Abstract

On February 25, 2009, a panel of international experts on plasma cell dyscrasia and skeletal disease met to discuss monoclonal gammopathy of undetermined significance (MGUS). This non-malignant B-cell disorder is the most common plasma cell dyscrasia and is associated with an increased risk of developing serious B-cell disorders. Individuals with MGUS also have an increased risk of osteoporosis and osteopenia associated with an increased likelihood of developing fractures especially in the vertebral column, peripheral neuropathy and thromboembolic events. The goal of the meeting was to develop a consensus statement regarding the appropriate tests to screen, evaluate and follow-up patients with MGUS. The panel also addressed the identification and treatment of MGUS-related skeletal problems, thromboembolic events and neurological complications. The following consensus statement outlines the conclusions and marks the first time that a consensus statement for the screening and treatment of MGUS has been clearly stated.

Original languageEnglish (US)
Pages (from-to)28-38
Number of pages11
JournalBritish Journal of Haematology
Volume150
Issue number1
DOIs
StatePublished - Jul 2010

Fingerprint

Monoclonal Gammopathy of Undetermined Significance
Guidelines
Paraproteinemias
B-Lymphocytes
Metabolic Bone Diseases
Peripheral Nervous System Diseases
Osteoporosis
Spine
Therapeutics

Keywords

  • Fractures
  • Monoclonal gammopathy of undetermined significance
  • Osteoporosis
  • Peripheral neuropathy

ASJC Scopus subject areas

  • Hematology

Cite this

Berenson, J. R., Anderson, K. C., Audell, R. A., Boccia, R. V., Coleman, M., Dimopoulos, M. A., ... Kyle, R. A. (2010). Monoclonal gammopathy of undetermined significance: A consensus statement: Guideline. British Journal of Haematology, 150(1), 28-38. https://doi.org/10.1111/j.1365-2141.2010.08207.x

Monoclonal gammopathy of undetermined significance : A consensus statement: Guideline. / Berenson, James R.; Anderson, Kenneth C.; Audell, Robert A.; Boccia, Ralph V.; Coleman, Morton; Dimopoulos, Meletios A.; Drake, Matthew M; Fonseca, Rafael; Harousseau, Jean Luc; Joshua, Douglas; Lonial, Sagar; Niesvizky, Ruben; Palumbo, Antonio; Roodman, G. David; San-Miguel, Jesus F.; Singhal, Seema; Weber, Donna M.; Zangari, Maurizio; Wirtschafter, Eric; Yellin, Ori; Kyle, Robert A.

In: British Journal of Haematology, Vol. 150, No. 1, 07.2010, p. 28-38.

Research output: Contribution to journalArticle

Berenson, JR, Anderson, KC, Audell, RA, Boccia, RV, Coleman, M, Dimopoulos, MA, Drake, MM, Fonseca, R, Harousseau, JL, Joshua, D, Lonial, S, Niesvizky, R, Palumbo, A, Roodman, GD, San-Miguel, JF, Singhal, S, Weber, DM, Zangari, M, Wirtschafter, E, Yellin, O & Kyle, RA 2010, 'Monoclonal gammopathy of undetermined significance: A consensus statement: Guideline', British Journal of Haematology, vol. 150, no. 1, pp. 28-38. https://doi.org/10.1111/j.1365-2141.2010.08207.x
Berenson, James R. ; Anderson, Kenneth C. ; Audell, Robert A. ; Boccia, Ralph V. ; Coleman, Morton ; Dimopoulos, Meletios A. ; Drake, Matthew M ; Fonseca, Rafael ; Harousseau, Jean Luc ; Joshua, Douglas ; Lonial, Sagar ; Niesvizky, Ruben ; Palumbo, Antonio ; Roodman, G. David ; San-Miguel, Jesus F. ; Singhal, Seema ; Weber, Donna M. ; Zangari, Maurizio ; Wirtschafter, Eric ; Yellin, Ori ; Kyle, Robert A. / Monoclonal gammopathy of undetermined significance : A consensus statement: Guideline. In: British Journal of Haematology. 2010 ; Vol. 150, No. 1. pp. 28-38.
@article{e85acffa4f3b4ad181d242171dd3afe2,
title = "Monoclonal gammopathy of undetermined significance: A consensus statement: Guideline",
abstract = "On February 25, 2009, a panel of international experts on plasma cell dyscrasia and skeletal disease met to discuss monoclonal gammopathy of undetermined significance (MGUS). This non-malignant B-cell disorder is the most common plasma cell dyscrasia and is associated with an increased risk of developing serious B-cell disorders. Individuals with MGUS also have an increased risk of osteoporosis and osteopenia associated with an increased likelihood of developing fractures especially in the vertebral column, peripheral neuropathy and thromboembolic events. The goal of the meeting was to develop a consensus statement regarding the appropriate tests to screen, evaluate and follow-up patients with MGUS. The panel also addressed the identification and treatment of MGUS-related skeletal problems, thromboembolic events and neurological complications. The following consensus statement outlines the conclusions and marks the first time that a consensus statement for the screening and treatment of MGUS has been clearly stated.",
keywords = "Fractures, Monoclonal gammopathy of undetermined significance, Osteoporosis, Peripheral neuropathy",
author = "Berenson, {James R.} and Anderson, {Kenneth C.} and Audell, {Robert A.} and Boccia, {Ralph V.} and Morton Coleman and Dimopoulos, {Meletios A.} and Drake, {Matthew M} and Rafael Fonseca and Harousseau, {Jean Luc} and Douglas Joshua and Sagar Lonial and Ruben Niesvizky and Antonio Palumbo and Roodman, {G. David} and San-Miguel, {Jesus F.} and Seema Singhal and Weber, {Donna M.} and Maurizio Zangari and Eric Wirtschafter and Ori Yellin and Kyle, {Robert A.}",
year = "2010",
month = "7",
doi = "10.1111/j.1365-2141.2010.08207.x",
language = "English (US)",
volume = "150",
pages = "28--38",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Monoclonal gammopathy of undetermined significance

T2 - A consensus statement: Guideline

AU - Berenson, James R.

AU - Anderson, Kenneth C.

AU - Audell, Robert A.

AU - Boccia, Ralph V.

AU - Coleman, Morton

AU - Dimopoulos, Meletios A.

AU - Drake, Matthew M

AU - Fonseca, Rafael

AU - Harousseau, Jean Luc

AU - Joshua, Douglas

AU - Lonial, Sagar

AU - Niesvizky, Ruben

AU - Palumbo, Antonio

AU - Roodman, G. David

AU - San-Miguel, Jesus F.

AU - Singhal, Seema

AU - Weber, Donna M.

AU - Zangari, Maurizio

AU - Wirtschafter, Eric

AU - Yellin, Ori

AU - Kyle, Robert A.

PY - 2010/7

Y1 - 2010/7

N2 - On February 25, 2009, a panel of international experts on plasma cell dyscrasia and skeletal disease met to discuss monoclonal gammopathy of undetermined significance (MGUS). This non-malignant B-cell disorder is the most common plasma cell dyscrasia and is associated with an increased risk of developing serious B-cell disorders. Individuals with MGUS also have an increased risk of osteoporosis and osteopenia associated with an increased likelihood of developing fractures especially in the vertebral column, peripheral neuropathy and thromboembolic events. The goal of the meeting was to develop a consensus statement regarding the appropriate tests to screen, evaluate and follow-up patients with MGUS. The panel also addressed the identification and treatment of MGUS-related skeletal problems, thromboembolic events and neurological complications. The following consensus statement outlines the conclusions and marks the first time that a consensus statement for the screening and treatment of MGUS has been clearly stated.

AB - On February 25, 2009, a panel of international experts on plasma cell dyscrasia and skeletal disease met to discuss monoclonal gammopathy of undetermined significance (MGUS). This non-malignant B-cell disorder is the most common plasma cell dyscrasia and is associated with an increased risk of developing serious B-cell disorders. Individuals with MGUS also have an increased risk of osteoporosis and osteopenia associated with an increased likelihood of developing fractures especially in the vertebral column, peripheral neuropathy and thromboembolic events. The goal of the meeting was to develop a consensus statement regarding the appropriate tests to screen, evaluate and follow-up patients with MGUS. The panel also addressed the identification and treatment of MGUS-related skeletal problems, thromboembolic events and neurological complications. The following consensus statement outlines the conclusions and marks the first time that a consensus statement for the screening and treatment of MGUS has been clearly stated.

KW - Fractures

KW - Monoclonal gammopathy of undetermined significance

KW - Osteoporosis

KW - Peripheral neuropathy

UR - http://www.scopus.com/inward/record.url?scp=77953482825&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953482825&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2141.2010.08207.x

DO - 10.1111/j.1365-2141.2010.08207.x

M3 - Article

C2 - 20507313

AN - SCOPUS:77953482825

VL - 150

SP - 28

EP - 38

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 1

ER -